Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Current Signal: SELL (auto-tracking)
0.38% $26.49
America/New_York / 19 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 377.11 mill |
EPS: | 0.390 |
P/E: | 67.92 |
Earnings Date: | Apr 30, 2024 |
SharesOutstanding: | 14.24 mill |
Avg Daily Volume: | 0.0620 mill |
RATING 2024-04-19 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Buy | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 67.92 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.31x |
Company: PE 67.92 | industry: PE 222.16 |
DISCOUNTED CASH FLOW VALUE |
---|
$3.02 (-88.61%) $-23.47 |
Date: 2024-04-19 |
Expected Trading Range (DAY) |
---|
$ 25.34 - 27.65 ( +/- 4.36%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-08 | Bedoya Jose H | Buy | 3 932 | Common Stock |
2024-02-08 | Bedoya Jose H | Buy | 1 803 | Common Stock |
2024-02-08 | Bedoya Jose H | Sell | 2 954 | Common Stock |
2024-02-08 | Bedoya Jose H | Buy | 3 853 | Stock Option (right to buy) |
2024-02-08 | Bedoya Jose H | Sell | 3 932 | Stock Option (right to buy) |
INSIDER POWER |
---|
62.17 |
Last 100 transactions |
Buy: 596 624 | Sell: 112 163 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $26.49 (0.38% ) |
Volume | 0.0402 mill |
Avg. Vol. | 0.0620 mill |
% of Avg. Vol | 64.81 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:33 | buy | $31.85 | N/A | Active |
---|
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The IVD segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.